Skip to main content
SpringerLink
Log in
Book cover

Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology pp 583–614Cite as

rhEPO in hematopoietic stem cell transplantation

  • Chapter

  • 902 Accesses

Abstract

Erythropoietin (Epo) is the critical regulatory factor of erythropoiesis, and recombinant human erythropoietin (rhEPO) has become a well-established treatment for chronic renal failure patients. In these subjects, endogenous serum Epo levels are very low (Erslev 1991) and the administration of rhEPO, restoring adequate levels of the hormone, permits correction of the anemia (Eschbach et al. 1987). In patients with normal kidney function, serum Epo levels increase exponentially when an anemia develops (Erslev 1991). After high-dose chemotherapy, serum Epo levels first rapidly increase to disproportionately high levels for 1–3 weeks, with peak values usually observed in the first week after the conditioning regimen (Birgegard et al. 1989; Abedi et al. 1990; Schapira et al. 1990; Beguin et al. 1991; Bosi et al. 1991a; Bosi et al. 1991b; Grace et al. 1991; Lazarus et al. 1992; Miller et al. 1992a; Beguin et al. 1993; Davies et al. 1995; Beguin et al. 1998). However, after allogeneic hematopoietic stem cell transplantation (HSCT) the Epo response to anemia then generally becomes impaired, resulting in inappropriately low levels of Epo for the degree of anemia and prolonged anemia (Ireland et al. 1990; Schapira et al. 1990; Beguin et al. 1991; Bosi et al. 1991a; Miller et al. 1992a; Beguin et al. 1993).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abedi MR, Backman L, Bostrom L, Lindback B, Ringden O (1990) Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation. Bone Marrow Transplant 6: 121–126

    CAS  PubMed  Google Scholar 

  2. Akiyama H, Tanikawa S, Takamoto S, Sakamaki H, Sasaki T, Onozawa Y (1994) Recombinant human erythropoietin (EPO) administration to marrow donors. Blood 84 [Suppl 1]: 732a (Abstract)

    Google Scholar 

  3. Ayash LJ, Elias A, Hunt M, Demetri G, Wheeler C, Tepler I, Schwartz G, Mazanet R, Reich E, McCauley M, Antman K, Anderson KC (1994) Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. Br J Haematol 87: 153–161

    Article  CAS  PubMed  Google Scholar 

  4. Baron F, Beguin Y (2002a) Nonmyeloablative allogeneic hematopoietic stem cell transplantation. J Hematother Stem Cell Res 11: 243–263

    Article  CAS  PubMed  Google Scholar 

  5. Baron F, Fillet G, Beguin Y (2002b) Erythropoiesis after nonmyeloablative stemcell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation. Transplantation 74: 1692–1696

    Article  CAS  PubMed  Google Scholar 

  6. Baron F, Frere P, Beguin Y (2003a) Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftment. Haematologica 88: 718–720

    PubMed  Google Scholar 

  7. Baron F, Frere P, Fillet G, Beguin Y (2003b) Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. Clin Cancer Res 9: 5566–5572

    CAS  PubMed  Google Scholar 

  8. Baron F, Frere P, Fillet G, Beguin Y (2003c) Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion. Br J Haematol 123: 103–105

    Article  CAS  PubMed  Google Scholar 

  9. Vanstraelen G, Baron F, Frere P, Hafraoui K, Fillet G, Beguin Y (2005) Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation. Haematologica 90: 1269–1270

    CAS  PubMed  Google Scholar 

  10. Baron F, Sautois B, Baudoux E, Matus G, Fillet G, Beguin Y (2002c) Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. Exp Hematol 30: 546–554

    Article  CAS  PubMed  Google Scholar 

  11. Beguin Y, Baron F, Fillet G (1998) Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. Haematologica 83: 1076–1081

    CAS  PubMed  Google Scholar 

  12. Beguin Y, Clemons GK, Oris R, Fillet G (1991) Circulating erythropoietin levels after bone marrow transplantation: Inappropriate response to anemia in allogeneic transplants. Blood 77: 868–873

    CAS  PubMed  Google Scholar 

  13. Beguin Y, Oris R, Fillet G (1993) Dynamics of erythropoietic recovery after bone marrow transplantation: role of marrow proliferative capacity and erythropoietin production in autologous versus allogeneic transplants. Bone Marrow Transplant 11: 285–292

    CAS  PubMed  Google Scholar 

  14. Benedetti PP, Pierelli L, Scambia G, Foddai ML, Salerno MG, Menichella G, Vittori M, Maneschi F, Caracussi U, Serafini R, Leone G, Mancuso S (1997) Highdose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration. Br J Cancer 75: 1205–1212

    Google Scholar 

  15. Biggs JC, Atkinson KA, Booker V, Concannon A, Dart GW, Dodds A, Downs K, Szer J, Turner J, Worthington R (1995) Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. the Australian Bone Marrow Transplant Study Group. Bone Marrow Transplant 15: 129–134

    CAS  PubMed  Google Scholar 

  16. Birgegard G, Wide L, Simonsson B (1989) Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation. Br J Haematol 72: 462–466

    Article  CAS  PubMed  Google Scholar 

  17. Bosi A, Vannucchi AM, Grossi A, Guidi S, Saccardi R, Rafanelli D, Longo G, Ferrini PR (1991a) Inadequate erythropoietin production in allogeneic bone marrow transplant patients. Haematologica 76: 280–284

    CAS  PubMed  Google Scholar 

  18. Bosi A, Vannucchi AM, Grossi A, Guidi S, Vannucchi L, Saccardi R, Bernabei PA, Longo G, Rafanelli D, Rossi Ferrini P (1991b) Serum erythropoietin levels in patients undergoing autologous bone marrow transplantation. Bone Marrow Transplant 7: 421–425

    CAS  PubMed  Google Scholar 

  19. Bowen DT, Janowska-Wieczorek A (1990) Serum erythropoietin following cytostatic therapy [letter]. Br J Haematol 74: 372–373

    Article  CAS  PubMed  Google Scholar 

  20. Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, Beguin Y (1998) Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 91: 2139–2145

    CAS  PubMed  Google Scholar 

  21. Chao NJ, Schriber JR, Long GD, Negrin RS, Catolico M, Brown BW, Miller LL, Blume KG (1994) A randomized study of erythropoietin and granulocyte colonystimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin’s and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Blood 83: 2823–2828

    CAS  PubMed  Google Scholar 

  22. Chuncharunee S, Carter CD, Studtmann KE, Caro J, Coffey RJ, Dessypris EN (1993) Chronic administration of transforming growth factor-beta suppresses erythropoietin-dependent erythropoiesis and induces tumour necrosis factor in vivo. Br J Haematol 84: 374–380

    Article  CAS  PubMed  Google Scholar 

  23. Davies SV, Fegan CD, Kendall R, Beguin Y, Cavill I (1995) Serum erythropoietin during autologous bone marrow transplantation: relationship to measures of erythroid activity. Clin Lab Haematol 17: 139–144

    CAS  PubMed  Google Scholar 

  24. de la Serna J, Bornstein R, Garcia-Bueno MJ, Lahuerta-Palacios JJ (1999) Iron depletion by phlebotomy with recombinant erythropoietin prior to allogeneic transplantation to prevent liver toxicity. Bone Marrow Transplant 23: 95–97

    Article  PubMed  Google Scholar 

  25. Erslev AJ (1991) Erythropoietin titers in health and disease. Semin Hematol 28 [Suppl 3]: 2–7

    CAS  PubMed  Google Scholar 

  26. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316: 73–78

    CAS  PubMed  Google Scholar 

  27. Estrin JT, Ford PA, Henry DH, Stradden AP, Mason BA (1997) Erythropoietin permits high-dose chemotherapy with peripheral blood stem-cell transplant for a Jehovah’s Witness [letter]. Am J Hematol 55: 51–52

    Article  CAS  PubMed  Google Scholar 

  28. Fandrey J, Jelkmann WE (1991) Interleukin-1 and tumor necrosis factor-alpha inhibit erythropoietin production in vitro. Ann NY Acad Sci 628: 250–255

    Article  CAS  PubMed  Google Scholar 

  29. Faquin WC, Schneider TJ, Goldberg MA (1992) Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79: 1987–1994

    CAS  PubMed  Google Scholar 

  30. Ferrara JL, Cooke KR, Teshima T (2003) The pathophysiology of acute graftversushost disease. Int J Hematol 78: 181–187

    Article  CAS  PubMed  Google Scholar 

  31. Ferrari S, Danova M, Porta C, Comolli G, Brugnatelli S, Pugliese P, Riccardi A, Ascari E (1999) Circulating progenitor cell release and functional characterization after topotecan plus G-CSF and erythropoietin in small cell lung cancer patients. Int J Oncol 15: 811–815

    CAS  PubMed  Google Scholar 

  32. Filip S, Vanasek J, Blaha M, Mericka P, Vavrova J, Podzimek K (1999) The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients. Neoplasma 46: 166–172

    CAS  PubMed  Google Scholar 

  33. Filip S, Vanasek J, Blaha M, Vavrova J (1997) Circulation of progenitor cells after intensive chemotherapy followed by combination G-CSF and EPO in breast carcinoma. Neoplasma 44: 212–218

    CAS  PubMed  Google Scholar 

  34. Frede S, Fandrey J, Pagel H, Hellwig T, Jelkmann W (1997) Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 beta injections in rats. Am J Physiol 273: R1067–R1071

    CAS  PubMed  Google Scholar 

  35. Fujimori Y, Kanamaru A, Saheki K, Mori A, Takatsuka H, Wada H, Okada M, Tamura S, Okamoto T, Takemoto Y, Kakishita E, Nagai K (1998) Recombinant human erythropoietin for late-onset anemia after allogeneic bone marrow transplantation. Int J Hematol 67: 131–136

    Article  CAS  PubMed  Google Scholar 

  36. Fujisawa S, Maruta A, Sakai R, Taguchi J, Tomita N, Ogawa K, Kodama F, Takahashi K, Shibayama S, Kobayashi S, Ikuta K, Okubo T (1996) Pure red cell aplasia after major ABO-incompatible bone marrow transplantation: two case reports of treatment with recombinant human erythropoietin. Transpl Int 9: 506–508

    Article  CAS  PubMed  Google Scholar 

  37. Grace RJ, Kendall RG, Chapman C, Hartley AE, Barnard DL, Norfolk DR (1991) Changes in serum erythropoietin levels during allogeneic bone marrow transplantation. Eur J Haematol 47: 81–85

    CAS  PubMed  Google Scholar 

  38. Heyll A, Aul C, Runde V, Arning M, Schneider W, Wernet P (1991) Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation with recombinant erythropoietin [letter]. Blood 77: 906

    CAS  PubMed  Google Scholar 

  39. Hunault-Berger M, Tanguy-Schmidt A, Rachieru P, Levy V, Truchan-Graczyk M, Francois S, Gardembas-Pain M, Dib M, Foussard C, Piard N, Godon A, Solal-Celigny P, Ifrah N (2005) rHuEpo before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: a pilot study. Bone Marrow Transplant 35: 903–907

    Article  CAS  PubMed  Google Scholar 

  40. Ireland RM, Atkinson K, Concannon A, Dodds A, Downs K, Biggs JC (1990) Serum erythropoietin changes in autologous and allogeneic bone marrow transplant patients. Br J Haematol 76: 128–134

    Article  CAS  PubMed  Google Scholar 

  41. Jelkmann W, Pagel H, Wolff M, Fandrey J (1992) Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 50: 301–308

    Article  CAS  PubMed  Google Scholar 

  42. Jelkmann W, Wolff M, Fandrey J (1990) Modulation of the production of erythropoietin by cytokines: in vitro studies and their clinical implications. Contrib Nephrol 87: 68–77

    CAS  PubMed  Google Scholar 

  43. Joshi SS, Miller K, Jackson JD, Warkentin P, Kessinger A (2000) Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin + G-CSF in cancer patients. Cytotherapy 2: 15–24

    Article  CAS  PubMed  Google Scholar 

  44. Kessinger A, Bishop MR, Jackson JD, O’Kane-Murphy B, Vose JM, Bierman PJ, Reed EC, Warkentin PI, Armitage JO, Sharp JG (1995) Erythropoietin for mobilization of circulating progenitor cells in patients with previously treated relapsed malignancies. Exp Hematol 23: 609–612

    CAS  PubMed  Google Scholar 

  45. Klaesson S, Ringden O, Ljungman P, Lonnqvist B, Wennberg L (1994a) Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 13: 397–402

    CAS  PubMed  Google Scholar 

  46. Klaesson S, Ringden O, Ljungman P, Lonnqvist B, Wennberg L (1994b) Treatment with erythropoietin after allogeneic bone marrow transplantation: a randomized, double-blind study. Transplant Proc 26: 1827–1828

    CAS  PubMed  Google Scholar 

  47. Lacey SF, Diamond DJ, Zaia JA (2004) Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant 10: 433–447

    Article  PubMed  Google Scholar 

  48. Lazarus HM, Goodnough LT, Goldwasser E, Long G, Arnold JL, Strohl KP (1992) Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: implications for erythropoietin therapy in this setting. Bone Marrow Transplant 10: 71–75

    CAS  PubMed  Google Scholar 

  49. Lin AC, Goldwasser E, Bernard EM, Chapman SW (1990) Amphotericin B blunts erythropoietin response to anemia. J Infect Dis 161: 348–351

    CAS  PubMed  Google Scholar 

  50. Link H, Boogaerts MA, Fauser AA, Slavin S, Reiffers J, Gorin NC, Carella AM, Mandelli F, Burdach S, Ferrant A, Linkesch W, Tura S, Bacigalupo A, Schindel F, Heinrichs H (1994) A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 84: 3327–3325

    CAS  PubMed  Google Scholar 

  51. Link H, Brune T, Hubner G, Diedrich H, Freund M, Stoll M, Peest D, Ebell W, Bettoni C, Oster W, Nicolay U, Heinrichs H (1993) Effect of recombinant human erythropoietin after allogenic bone marrow transplantation. Ann Hematol 67: 169–173

    Article  CAS  PubMed  Google Scholar 

  52. Locatelli F, Pedrazzoli P, Barosi G, Zecca M, Porta F, Liberato L, Gambarana D, Nespoli L, Cazzola M (1992) Recombinant human erythropoietin is effective in correcting erythropoietin-deficient anaemia after allogeneic bone marrow transplantation. Br J Haematol 80: 545–549

    Article  CAS  PubMed  Google Scholar 

  53. Locatelli F, Zecca M, Beguin Y, Giorgiani G, Ponchio L, De Stefano P, Cazzola M (1993) Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation. Br J Haematol 84: 752–754

    Article  CAS  PubMed  Google Scholar 

  54. Locatelli F, Zecca M, Pedrazzoli P, Prete L, Quaglini S, Comoli P, De Stefano P, Beguin Y, Robustelli della Cuna G, Severi F, Cazzola M (1994a) Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 13: 403–410

    CAS  PubMed  Google Scholar 

  55. Locatelli F, Zecca M, Ponchio L, Beguin Y, Giorgiani G, Maccario R, Bonetti F, De Stephano P, Cazzola M (1994b) Pilot trial of combined administration of erythropoietin and granulocyte colony-stimulating factor to children undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 14: 929–935

    CAS  PubMed  Google Scholar 

  56. Lopez J, Steegmann JL, Perez G, Otero MJ, Berberana M, Camara R, Lamana M, Fernandez Villalta MJ, Fernandez-Ranada JM (1994) Erythropoietin in the treatment of delayed immune hemolysis of a major ABO-incompatible bone marrow transplant. Am J Hematol 45: 237–239

    Article  CAS  PubMed  Google Scholar 

  57. Mann RA, Jetzt AE, Singh M, Singh AB (1996) The effect of erythropoietin administration on murine bone marrow chimeras. Immunol Lett 49: 15–20

    Article  CAS  PubMed  Google Scholar 

  58. Martelli M, Ponchio L, Beguin Y, Meloni G, Mandelli F, Cazzola M (1994) Pure red cell aplasia following peripheral stem cell transplantation: complete response to a short course of high-dose recombinant human erythropoietin. Haematologica 79: 456–459

    CAS  PubMed  Google Scholar 

  59. Martinez AM, Sastre A, Munoz A, Badell I, Maldonado MS, Cubells J (1998) Recombinant human erythropoietin (rh-Epo) administration to normal child bone marrow donors. Bone Marrow Transplant 22: 137–138

    Article  CAS  PubMed  Google Scholar 

  60. Miller CB, Jones RJ, Zahurak ML, Piantadosi S, Burns WH, Santos GW, Spivak JL (1992a) Impaired erythropoietin response to anemia after bone marrow transplantation. Blood 80: 2677–2682

    CAS  PubMed  Google Scholar 

  61. Miller CB, Mills S (1994) Erythropoietin after bone marrow transplantation. Hematol Oncol Clin North Am 8: 975–992

    CAS  PubMed  Google Scholar 

  62. Miller KL, Carlino JA, Ogawa Y, Avis PD, Carroll KG (1992b) Alterations in erythropoiesis in TGF-beta 1-treated mice. Exp Hematol 20: 951–956

    CAS  PubMed  Google Scholar 

  63. Mitus AJ, Antin JH, Rutherford CJ, McGarigle CJ, Goldberg MA (1994) Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs. Blood 83: 1952–1957

    CAS  PubMed  Google Scholar 

  64. Nguyen VA, Fauser AA, Basara N, Kiehl M (2003) Erythropoietic recovery during treatment with darbepoietin-alpha after impaired rHuEPO response to anemia in two patients with osteomyelofibrosis after peripheral blood stem cell transplantation. Hematol J 4: 456–458

    Article  PubMed  Google Scholar 

  65. Nieken J, Mulder NH, Buter J, Vellenga E, Limburg PC, Piers DA, de Vries EG (1995) Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 86: 900–905

    CAS  PubMed  Google Scholar 

  66. O’Kane-Murphy B, Jackson JD, Kuszynski C, Costas P, Wang PN, Warkentin PI, Kessinger A (1994) CD34 analysis in erythropoietin mobilized peripheral blood stem cells. Prog Clin Biol Res 389: 371–376

    PubMed  Google Scholar 

  67. Ohashi K, Akiyama H, Takamoto S, Tanikawa S, Sakamaki H, Onozawa Y (1994) Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistant to erythropoietin. Bone Marrow Transplant 13: 335–336

    CAS  PubMed  Google Scholar 

  68. Olivieri A, Offidani M, Cantori I, Ciniero L, Ombrosi L, Masia MC, Brunori M, Montroni M, Leoni P (1995) Addition of erythropoietin to granulocyte colonystimulating factor after priming chemotherapy enhances hemopoietic progenitor mobilization. Bone Marrow Transplant 16: 765–770

    CAS  PubMed  Google Scholar 

  69. Olivieri A, Scortechini I, Capelli D, Montanari M, Lucesole M, Gini G, Troiani M, Offidani M, Poloni A, Masia MC, Raggetti GM, Leoni P (2004) Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. Bone Marrow Transplant 34: 693–702

    Article  CAS  PubMed  Google Scholar 

  70. Paltiel O, Cournoyer D, Rybka W (1993) Pure red cell aplasia following ABOincompatible bone marrow transplantation: response to erythropoietin. Transfusion 33: 418–421

    Article  CAS  PubMed  Google Scholar 

  71. Pedrazzini A (1993) Erythropoietin and GM-CSF following autologous bone marrow transplantation. Eur J Cancer 29 [Suppl 2]: S15–S17

    Article  Google Scholar 

  72. Pene R, Appelbaum FR, Fisher L, Lilleby K, Nemunaitis J, Storb R, Buckner CD (1993) Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation. Bone Marrow Transplant 11: 219–222

    CAS  PubMed  Google Scholar 

  73. Perillo A, Pierelli L, Battaglia A, Salerno MG, Rutella S, Cortesi E, Fattorossi A, De Rosa L, Ferrau F, Lalle M, Leone G, Mancuso S, Scambia G (2002) Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer. Bone Marrow Transplant 30: 571–578

    Article  CAS  PubMed  Google Scholar 

  74. Perillo A, Pierelli L, Scambia G, Serafini R, Paladini U, Salerno MG, Bonanno G, Fattorossi A, Leone G, Mancuso S, Menichella G (2001) Peripheral blood progenitor cell collection after epirubicin, paclitaxel, and cisplatin combination chemotherapy using EPO-based cytokine regimens: a randomized comparison of G-CSF and sequential GM-/G-CSF. Transfusion 41: 674–680

    Article  CAS  PubMed  Google Scholar 

  75. Pettengell R, Woll PJ, Chang J, Coutinho L, Testa NG, Crowther D (1994) Effects of erythropoietin on mobilisation of haemopoietic progenitor cells. Bone Marrow Transplant 14: 125–130

    CAS  PubMed  Google Scholar 

  76. Pierelli L, Menichella G, Scambia G, Teofili L, Iovino S, Serafini R, Benedetti Panici P, Salerno G, Rumi C, Zini G, d’Onofrio G, Leone G, Mancuso S, Bizzi B (1994) In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells. Bone Marrow Transplant 14: 23–30

    CAS  PubMed  Google Scholar 

  77. Pierelli L, Perillo A, Greggi S, Salerno G, Panici PB, Menichella G, Fattorossi A, Leone G, Mancuso S, Scambia G (1999) Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J Clin Oncol 17: 1288–1295

    CAS  PubMed  Google Scholar 

  78. Pierelli L, Scambia G, Menichella G, d’Onofrio G, Salerno G, Panici PB, Foddai ML, Vittori M, Lai M, Ciarli M, Puglia G, Mancuso S, Bizzi B (1996) The combination of erythropoietin and granulocyte colony-stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation. Br J Haematol 92: 287–294

    Article  CAS  PubMed  Google Scholar 

  79. Ponchio L, Zambelli A, De Stefano A, Robustelli Della Cuna FS, Perotti C, Pedrazzoli P (2000) Transfusion requirement can be abolished by epoietin-α and autologous platelet predeposit in patients receiving high dose chemotherapy with stem cell support [letter]. Haematologica 85: 219–220

    CAS  PubMed  Google Scholar 

  80. Santamaria A, Sureda A, Martino R, Domingo-Albos A, Muniz-Diaz E, Brunet S (1997) Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. Bone Marrow Transplant 20: 1105–1107

    Article  CAS  PubMed  Google Scholar 

  81. Sautois B, Baudoux E, Salmon JP, Michaux S, Schaaf-Lafontaine N, Pereira M, Paulus JM, Fillet G, Beguin Y (2001) Administration of erythropoietin and granulocyte colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor cells (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC transplantation. Haematologica 86: 1209–1218

    CAS  PubMed  Google Scholar 

  82. Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Goldberg MA (1990) Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 76: 2354–2359

    CAS  PubMed  Google Scholar 

  83. Steegmann JL, Lopez J, Otero MJ, Lamana ML, de la Camara R, Berberana M, Diaz A, Fernandez-Ranada JM (1992) Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. Bone Marrow Transplant 10: 541–546

    CAS  PubMed  Google Scholar 

  84. Taniguchi S, Yamasaki K, Shibuya T, Asayama R, Harada M, Niho Y (1993) Recombinant human erythropoietin for long-term persistent anemia after major ABO-incompatible bone marrow transplantation [letter]. Bone Marrow Transplant 12: 423

    CAS  PubMed  Google Scholar 

  85. Ustun C, Celebi H, Arat M, Ozcan M, Dilek I, Gurman G, Demirer T, Ilhan O, Keskin R, Koc H (1999) Treatment of aregeneratoric anemia following an ABOincompatible allogeneic peripheral blood stem cell transplantation: a case report. Ther Apher 3: 275–277

    Article  CAS  PubMed  Google Scholar 

  86. van den Bent MJ, Bos GM, Sillevis Smitt PA, Cornelissen JJ (1999) Erythropoietin induced visual hallucinations after bone marrow transplantation [letter]. J Neurol 246: 614–616

    Article  PubMed  Google Scholar 

  87. Vannucchi AM, Bosi A, Grossi A, Guidi S, Saccardi R, Lombardini L, Rossi Ferrini P (1992) Stimulation of erythroid engraftment by recombinant human erythropoietin in ABO-compatible, HLA-identical, allogeneic bone marrow transplant patients. Leukemia 6: 215–219

    CAS  PubMed  Google Scholar 

  88. Vannucchi AM, Bosi A, Grossi A, Guidi S, Saccardi R, Rossi-Ferrini P (1994a) Down-modulation of serum erythropoietin levels following cyclosporin A infusion [letter]. Bone Marrow Transplant 13: 497–498

    CAS  PubMed  Google Scholar 

  89. Vannucchi AM, Bosi A, Ieri A, Guidi S, Saccardi R, Lombardini L, Linari S, Laszlo D, Longo G, Rossi-Ferrini P (1996) Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Bone Marrow Transplant 17: 527–531

    CAS  PubMed  Google Scholar 

  90. Vannucchi AM, Bosi A, Linari S, Guidi S, Longo G, Lombardini L, Mariani MP, Saccardi R, Laszlo D, Rossi FP (1997) High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study. Haematologica 82: 53–56

    CAS  PubMed  Google Scholar 

  91. Vannucchi AM, Grossi A, Bosi A, Rafanelli D, Guidi S, Saccardi R, Alterini R, Ferrini PR (1991) Impaired erythropoietin production in mice treated with cyclosporin A. Blood 78: 1615–1618

    CAS  PubMed  Google Scholar 

  92. Vannucchi AM, Grossi A, Bosi A, Rafanelli D, Statello M, Guidi S, Rossi-Ferrini P (1993) Effects of cyclosporin A on erythropoietin production by the human Hep3B hepatoma cell line. Blood 82: 978–984

    CAS  PubMed  Google Scholar 

  93. Vannucchi AM, Grossi A, Rafanelli D, Statello M, Cinotti S, Rossi-Ferrini P (1994b) Inhibition of erythropoietin production in vitro by human interferon gamma. Br J Haematol 87: 18–23

    Article  CAS  PubMed  Google Scholar 

  94. Waller CF, von Lintig F, Daskalakis A, Musahl V, Lange W (1999) Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy. Bone Marrow Transplant 24: 19–24

    Article  CAS  PubMed  Google Scholar 

  95. York A, Clift RA, Sanders JE, Buckner CD (1992) Recombinant human erythropoietin (rh-Epo) administration to normal marrow donors. Bone Marrow Transplant 10: 415–417

    CAS  PubMed  Google Scholar 

  96. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF (1993) Structure, function, and activation of the erythropoietin receptor. Blood 81: 2223–2236

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology, University of Liège, Liège, Belgium

    Gaetan Van Straelen (Télévie Research Assistant of the National Fund for Scientific Research (FNRS, Belgium) & Prof. Yves Beguin MD (Research Director of the of the National Fund for Scientific Research (FNRS, Belgium)

  2. Center for Cellular and Molecular Therapy (Centre de Thérapie Cellulaire et Moléculaire, CTCM), University of Liège, Liège, Belgium

    Gaetan Van Straelen (Télévie Research Assistant of the National Fund for Scientific Research (FNRS, Belgium) & Prof. Yves Beguin MD (Research Director of the of the National Fund for Scientific Research (FNRS, Belgium)

Authors
  1. Gaetan Van Straelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Yves Beguin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yves Beguin MD .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine (Cancer Research), West German Cancer Center, University Hospital of Essen, Essen, Germany

    Mohammad Resa Nowrousian

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag/Wien

About this chapter

Cite this chapter

Van Straelen, G., Beguin, Y. (2008). rhEPO in hematopoietic stem cell transplantation. In: Nowrousian, M.R. (eds) Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Springer, Vienna. https://doi.org/10.1007/978-3-211-69459-6_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-69459-6_22

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-25223-9

  • Online ISBN: 978-3-211-69459-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation